Stocks · Korea
128940
KOSPI
Hanmi Pharm
An overview for this page is not available in English yet. The figures below are updated daily.
Key figures 2026-10-07 basis
PER39.93x
PBR5.42x
EPS13,372 KRW
BPS98,560 KRW
ROE13.09%
Dividend yield0.37%
DPS2,000 KRW
Payout ratio14.96%
Returns and 52-week range
1W+6.37%
1M+15.96%
3M+15.71%
6M-3.44%
1Y+48.13%
YTD+20.54%
52W high647,000원
52W low302,000원
From 52W high-17.47%
Financial results (consolidated)
| Period | Revenue | Operating income | Net income | OP margin |
|---|---|---|---|---|
| 2022 | 1.3조 | 1,581억 | 1,016억 | 11.9% |
| 2023 | 1.5조 | 2,207억 | 1,654억 | 14.8% |
| 2024 | 1.5조 | 2,162억 | 1,404억 | 14.5% |
| 2025 | 1.5조 | 2,578억 | 1,871억 | 16.7% |
| Quarterly | ||||
| 2024 4Q | 3,516억 | 305억 | -48억 | 8.7% |
| 2025 1Q | 3,909억 | 590억 | 447억 | 15.1% |
| 2025 2Q | 3,613억 | 604억 | 430억 | 16.7% |
| 2025 3Q | 3,623억 | 551억 | 454억 | 15.2% |
| 2025 4Q | 4,330억 | 833억 | 541억 | 19.2% |
| 2026 1Q | 3,929억 | 536억 | 511억 | 13.7% |
Company
Address: 경기도 화성시 팔탄면 무하로 214
Peers in the same sector
Recent filings
- 2026-08-14반기보고서 (2026.06)
- 2026-07-28주요사항보고서(자기주식처분결정) Major
- 2026-05-15분기보고서 (2026.03)
- 2026-03-20사업보고서 (2025.12)
- 2026-01-09주요사항보고서(자기주식처분결정) Major
- 2025-11-14분기보고서 (2025.09)
- 2025-08-14[기재정정]반기보고서 (2025.06)
- 2025-08-14반기보고서 (2025.06)
- 2025-05-15분기보고서 (2025.03)
Source: DART (Financial Supervisory Service electronic disclosure)
Recent news
- 2026-10-07국산 첫 GLP-1 비만치료제 허가⋯한미약품 ‘에페’ 45번째 신약 코메디닷컴
- 2026-10-07한국판 위고비·마운자로 나온다… 한미약품 ‘에페’ 식약처 허가 세계일보
- 2026-10-07한미약품 비만치료제 '에페' 허가…위고비·마운자로와 3파전 비즈워치
- 2026-10-07한미약품 '에페' 허가...국산 1호 GLP-1 비만치료제 출시 한국경제TV
- 2026-10-07한국판 위고비·마운자로 온다…한미약품 '에페' 식약처 허가 한국경제
- 2026-10-07한미약품 첫 비만약 '에페', 45번째 국산 신약 등극 데일리안
- 2026-10-07'한국인 맞춤 비만신약' 나온다⋯한미약품 '에페' 허가 아이뉴스24
- 2026-10-07국산 첫 GLP-1 비만 치료제 나왔다…한미약품 ‘에페’ 허가 부산일보
Sources and notes
This page summarizes public filings, market data and news for information only. It is not a recommendation to buy or sell any security. Figures are as of the dates shown; check the original filings before making decisions.